-
Time:2026-07-09tricision's independently developed Survivin-TargetingDendritic Cell (DC) Cell Injection has reached two major milestones inrapid succession: the Center for Drug Evaluation (CDE) haspublicly listed th -
Time:2026-07-09When standard treatment options reach theirlimits, Clinical Trials (CTs) can offer a new ray of hope.This guide provides a clear roadmap for Glioblastoma Multiforme (GBM) patientsand their families on -
Time:2026-07-09The immune system's ability to recognizeand eliminate cancer cells depends on tumor antigens—molecularmarkers that distinguish malignant cells from healthy tissue. These antigensdetermine whether the -
Time:2026-07-09Glioblastoma Multiforme (GBM) is widely regarded as the "king of cancers"—arelentless and deadly adversary of the central nervous system. In China, theannual incidence is approximately 5–8 per 100,000 -
Time:2026-07-09At the start of 2025, China's firstMessenger RNA-Dendritic Cell (mRNA-DC) tumor vaccine for primary GlioblastomaMultiforme (GBM) began enrolling patients in a Phase IClinical Trial (CT) at Beijing Tia -
Time:2026-07-09On May 22, 2024, China ReformHealth and Beijing tricision Biotech Co., Ltd. (tricision) signed aStrategic Cooperation Agreement in Beijing—a milestone collaboration thatmarks a significant acceleratio -
Time:2026-07-09The "Tri-Medicine SynergyFuture Healthcare Conference" took place in Shanghai on April12–13, co-hosted by China Reform Fund, China Reform Health Managementand Services Group Co., Ltd. (China Reform He -
Time:2026-07-09On January 30, Beijing tricision Biotech Co., Ltd. (tricision) received the "Notification of Grant of Invention Patent Right" from the China National Intellectual Property Administration (CNIPA) for i -
Time:2026-07-09At the start of 2024, the world'sfirst Survivin-targeting Messenger RNA-Dendritic Cell (mRNA-DC) tumor vaccine forthe treatment of Glioblastoma Multiforme (GBM), developed byBeijing tricision Biotech -
Time:2026-07-09On December 8, the 8th "MakerChina" Beijing SME Innovation and Entrepreneurship Competition—also knownas "Maker Beijing 2023"—concluded successfully. Beijingtricision Biotech Co., Ltd. (tricision) was -
Time:2026-07-09On November 7, the Office of the NationalHigh-Tech Enterprise Recognition and Management Leading Group released the"2023 First Batch of High-Tech Enterprise Recognition List forBeijing." Beijing trici -
Time:2026-07-09Thermo Fisher Scientific Inc. (ThermoFisher) and Beijing tricision Biotech Co.,Ltd. (tricision) have signed a Memorandum of Understanding (MOU) for globalcommercial collaboration, building on their ex -
Time:2026-07-09Beijing tricision Biotech Co., Ltd.(tricision) and China Resources Biopharmaceutical Co., Ltd. (ChinaResources Biopharmaceutical) have announced that YixingChenggong New Drug Development Co., Ltd. (Ch -
Time:2026-07-09On February 20, the ChinaAssociation for Science and Technology (CAST) officially released theresults of its 2022 "Innovation China" series roster. Followingmultiple rounds of rigorous evaluation, Bei
一 ABOUT US
一 Research
一 Products & Service
一 Newsroom
